It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses.
Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
Sanofi is merging its real-world data platform with New York startup Aetion’s similar evidence platform to augment its treatment development and deployment efforts, the companies announced today. Sanofi’s DARWIN platform will provide a substantial body of de-identified patient data, which the Aetion Evidence Platform will analyze those information for insights on drug effectiveness, safety and...
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.
The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.
Sanofi is currently...
Startups can have a difficult time striking a balance between the fast pace of tech culture and healthcare’s slow-and-steady validation culture.
In part, the culture clash is a West Coast-East Coast divide, with tech giants congregating for the most part in California and hospitals and pharma in the Northeast, according to a panel moderated by CNBC’s Christina Farr at the MassBio Digital Health...
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.
Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects.
Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.
But that wasn’t the only advance in the space as pharma...
